This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Houghton, P. J. Articles by Smith, M. A. Search for Related Content PubMed PubMed Citation Articles by Houghton, P. J. Articles by Smith, M. A.

Testing of New Agents in Childhood Cancer Preclinical Models

Meeting Summary

St. Jude Children’s Research Hospital, Memphis, Tennessee 38101 [P. J. H.]; Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 [P. C. A., J. M. M.]; Texas Children’s Cancer Center, Houston, Texas 77024 [S. B.]; Neurologic Oncology Branch, Bethesda, Maryland 20892 [H. A. F.]; Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [R. G.]; Children’s Cancer Institute Australia for Medical Research, (affiliated with the University of New South Wales and Sydney Children’s Hospital), Randwick, New South Wales, Australia [M. H., R. B. L.]; Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892 [L. H.]; Food and Drug Administration, Rockville, Maryland 20852 [S. H.]; Biological Testing Branch, National Cancer Institute, Frederick, Maryland 21702 [M. G. H.]; Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, New Hampshire 03756 [M. A. I.]; Molecular Genetics Section, National Cancer Institute, Bethesda, Maryland 20892 [G. M.]; Technology Transfer Branch, National Cancer Institute, Bethesda, Maryland 20892 [W. P.]; Children’s Hospital of Los Angeles, Los Angeles, California 90027 [P. R.]; University of California San Francisco School Of Medicine, San Francisco, California 94143 [K. S.]; University of California San Diego Medical Center, San Diego, California 92103 [A. Y.]; The Scripps Research Institute, La Jolla, California 92037 [J. Y.]; and Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland 20892-7436 [M. A. S.]

ABSTRACT

A workshop on pediatric preclinical testing, sponsored by the National Cancer Institute and the Children’s Oncology Group Phase 1 Consortium, was held on June 26–27, 2001 in Bethesda, Maryland. Drs. Peter Adamson, Peter Houghton, and Malcolm Smith organized and hosted the meeting. There were 20 participants from 12 institutions. The primary objectives of the workshop included: (a) development of a working inventory of available preclinical models (including human tumor xenografts in immunodeficient mice, transgenic and syngeneic tumors, and selected in vitro models), with a basic understanding of the strengths and weaknesses of each as possible components of a preclinical testing program; (b) identification of the key scientific issues related to establishment of a program for preclinical testing of new agents for their applicability to childhood cancers; and (c) identification of the key infrastructure requirements for a program for preclinical testing of new agents for their applicability to childhood cancers. This report is a synthesis of the workshop’s presentations and discussions.

This article has been cited by other articles:

				G. Neale, X. Su, C. L. Morton, D. Phelps, R. Gorlick, R. B. Lock, C. P. Reynolds, J. M. Maris, H. S. Friedman, J. Dome, et al. Molecular Characterization of the Pediatric Preclinical Testing Panel Clin. Cancer Res., July 15, 2008; 14(14): 4572 - 4583. [Abstract] [Full Text] [PDF]

				V. Garg, W. Zhang, P. Gidwani, M. Kim, and E. A. Kolb Preclinical Analysis of Tasidotin HCl in Ewing's Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, and Osteosarcoma Clin. Cancer Res., September 15, 2007; 13(18): 5446 - 5454. [Abstract] [Full Text] [PDF]

				P. J. Houghton and C. L. Morton Rational Use of Human Tumor Xenografts for Drug Development Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 77 - 82. [Full Text] [PDF]

				A. S. Pappo, E. Lyden, P. Breitfeld, S. S. Donaldson, E. Wiener, D. Parham, K. R. Crews, P. Houghton, and W. H. Meyer Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group J. Clin. Oncol., February 1, 2007; 25(4): 362 - 369. [Abstract] [Full Text] [PDF]

				C. C. Whiteford, S. Bilke, B. T. Greer, Q. Chen, T. A. Braunschweig, N. Cenacchi, J. S. Wei, M. A. Smith, P. Houghton, C. Morton, et al. Credentialing Preclinical Pediatric Xenograft Models Using Gene Expression and Tissue Microarray Analysis Cancer Res., January 1, 2007; 67(1): 32 - 40. [Abstract] [Full Text] [PDF]

				C. Graham, C. Tucker, J. Creech, E. Favours, C. A. Billups, T. Liu, M. Fouladi, B. B. Freeman III, C. F. Stewart, and P. J. Houghton Evaluation of the Antitumor Efficacy, Pharmacokinetics, and Pharmacodynamics of the Histone Deacetylase Inhibitor Depsipeptide in Childhood Cancer Models In vivo Clin. Cancer Res., January 1, 2006; 12(1): 223 - 234. [Abstract] [Full Text] [PDF]

				V. M. Santana, W. L. Furman, C. A. Billups, F. Hoffer, A. M. Davidoff, P. J. Houghton, and C. F. Stewart Improved Response in High-Risk Neuroblastoma With Protracted Topotecan Administration Using a Pharmacokinetically Guided Dosing Approach J. Clin. Oncol., June 20, 2005; 23(18): 4039 - 4047. [Abstract] [Full Text] [PDF]

				P. J. Houghton Human Tumor Xenografts as Preclinical Models: Value and Limitations Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 33 - 37. [Full Text] [PDF]

				J. M. Gallo, P. Vicini, A. Orlansky, S. Li, F. Zhou, J. Ma, S. Pulfer, M. A. Bookman, and P. Guo Pharmacokinetic Model-Predicted Anticancer Drug Concentrations in Human Tumors Clin. Cancer Res., December 1, 2004; 10(23): 8048 - 8058. [Abstract] [Full Text] [PDF]

				J. C.L. Schuh Trials, Tribulations, and Trends in Tumor Modeling in Mice Toxicol Pathol, January 1, 2004; 32(1_suppl): 53 - 66. [Abstract] [PDF]

				R. Gorlick, P. Anderson, I. Andrulis, C. Arndt, G. P. Beardsley, M. Bernstein, J. Bridge, N.-K. Cheung, J. S. Dome, D. Ebb, et al. Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary Clin. Cancer Res., November 15, 2003; 9(15): 5442 - 5453. [Abstract] [Full Text] [PDF]